Trial Profile
A clinical study of PRO 140 for the treatment of colon carcinoma patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 30 Aug 2018
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications Carcinoma; Colon cancer
- Focus Therapeutic Use
- 30 Aug 2018 New trial record
- 15 Aug 2018 According to a CytoDyn media release, the company is planning to file an IND within the next few weeks to begin studies of PRO 140 for the treatment of colon carcinoma.